JP2023508250A - 軽度外傷性脳損傷の処置 - Google Patents

軽度外傷性脳損傷の処置 Download PDF

Info

Publication number
JP2023508250A
JP2023508250A JP2022564096A JP2022564096A JP2023508250A JP 2023508250 A JP2023508250 A JP 2023508250A JP 2022564096 A JP2022564096 A JP 2022564096A JP 2022564096 A JP2022564096 A JP 2022564096A JP 2023508250 A JP2023508250 A JP 2023508250A
Authority
JP
Japan
Prior art keywords
ghrelin
variant
days
mtbi
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508250A5 (https=
Inventor
バンサル，ビシャル
シャー，カルティ
ワイアンド，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxeia Biopharmaceuticals Inc
Original Assignee
Oxeia Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxeia Biopharmaceuticals Inc filed Critical Oxeia Biopharmaceuticals Inc
Publication of JP2023508250A publication Critical patent/JP2023508250A/ja
Publication of JP2023508250A5 publication Critical patent/JP2023508250A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022564096A 2019-12-23 2020-12-22 軽度外傷性脳損傷の処置 Pending JP2023508250A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953130P 2019-12-23 2019-12-23
US62/953,130 2019-12-23
PCT/US2020/066703 WO2021133844A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Publications (2)

Publication Number Publication Date
JP2023508250A true JP2023508250A (ja) 2023-03-01
JP2023508250A5 JP2023508250A5 (https=) 2024-01-04

Family

ID=76575665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564096A Pending JP2023508250A (ja) 2019-12-23 2020-12-22 軽度外傷性脳損傷の処置

Country Status (11)

Country Link
US (1) US20230031262A1 (https=)
EP (1) EP4081238A4 (https=)
JP (1) JP2023508250A (https=)
KR (1) KR20220122691A (https=)
CN (1) CN114980915A (https=)
AU (1) AU2020412765A1 (https=)
BR (1) BR112022012365A2 (https=)
CA (1) CA3165738A1 (https=)
IL (1) IL294156A (https=)
MX (1) MX2022007844A (https=)
WO (1) WO2021133844A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370804A1 (en) * 2021-01-22 2022-11-24 The Regents Of The University Of Colorado, A Body Corporate Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders
CN113723530B (zh) * 2021-09-02 2022-03-25 中国科学院自动化研究所 基于视频分析和电子心理沙盘的智能心理评估系统
AU2023338304A1 (en) * 2022-09-07 2025-04-10 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537173A (ja) * 2013-11-15 2016-12-01 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
JP2017506625A (ja) * 2014-02-05 2017-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 軽度脳損傷の治療方法
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
AU2015305647A1 (en) * 2014-08-19 2017-04-06 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
WO2016134215A1 (en) * 2015-02-19 2016-08-25 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder
US20180071367A1 (en) * 2015-03-09 2018-03-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537173A (ja) * 2013-11-15 2016-12-01 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
JP2017506625A (ja) * 2014-02-05 2017-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 軽度脳損傷の治療方法
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL TRANSPLANTATION, vol. Vol.26(7), JPN6025045127, 2017, pages 1131 - 1155, ISSN: 0005722570 *
PEPTIDES, vol. 54, JPN6025000112, 2014, pages 180 - 185, ISSN: 0005722571 *

Also Published As

Publication number Publication date
BR112022012365A2 (pt) 2022-08-30
CN114980915A (zh) 2022-08-30
CA3165738A1 (en) 2021-07-01
US20230031262A1 (en) 2023-02-02
AU2020412765A1 (en) 2022-07-14
WO2021133844A1 (en) 2021-07-01
EP4081238A4 (en) 2023-08-30
EP4081238A1 (en) 2022-11-02
MX2022007844A (es) 2022-09-07
IL294156A (en) 2022-08-01
KR20220122691A (ko) 2022-09-02

Similar Documents

Publication Publication Date Title
Busse et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma
Obermann et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial
Brown et al. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial
Friedman et al. Diazepam is no better than placebo when added to naproxen for acute low back pain
Warden et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury
Kwon et al. Acupuncture for the sequelae of Bell’s palsy: a randomized controlled trial
Feil et al. Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial
JP2023508250A (ja) 軽度外傷性脳損傷の処置
Rose et al. Treatment for inclusion body myositis
Hallas et al. Methodological analysis: randomized controlled trials for pfizer and moderna COVID-19 vaccines
Singappuli et al. Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions
Buta et al. Real-world evidence of allergen immunotherapy
Attallah et al. Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis
Mohammed et al. Side effects associated with homologous and heterologous COVID-19 vaccines: a cross-sectional study in Saudi Arabia
US20260077018A1 (en) Treatment of mild traumatic brain injury
Kwon et al. Acupuncture for sequelae of Bell's palsy: a randomized controlled trial protocol
HK40080092A (en) Treatment of mild traumatic brain injury
Khokhar et al. Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy
Kozlowska et al. Parkinson's disease gene therapy: a comparative effectiveness review of completed clinical trials in terms of their possible implementation in treatment
Yaeger et al. Ropivacaine intramuscular paracervical injections for pediatric headache: a randomized placebo-controlled trial
Vázquez-Doce et al. Effectiveness of repeated injections of botulinum toxin A on gait and fatigue in adults with spastic paraparesis secondary to multiple sclerosis
Deer et al. Safety and Efficacy of Intradiscal Nucleus Pulposus Allograft versus Sham for Lumbar Discogenic Pain Associated with Degenerative Disc Disease: Study Protocol for a Randomized Clinical Trial
CN121175045A (zh) 用于治疗夏科-马里-图思病的组合物和方法
Kim et al. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study
Al Al Hamoud et al. Impact of Immunotherapy on Refractory Allergic Rhinitis in Armed Force Hospital Southern Region, Saudi Arabia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260402